Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (DFPH) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to -$13.8 million.

  • Oncology Institute's Net Income towards Common Stockholders fell 413.67% to -$13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.2 million, marking a year-over-year increase of 987.37%. This contributed to the annual value of -$53.0 million for FY2024, which is 2191.02% up from last year.
  • Per Oncology Institute's latest filing, its Net Income towards Common Stockholders stood at -$13.8 million for Q3 2025, which was down 413.67% from -$14.0 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Net Income towards Common Stockholders registered a high of $19.3 million during Q1 2022, and its lowest value of -$30.0 million during Q1 2023.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$12.7 million (2024), whereas its average is -$10.8 million.
  • Per our database at Business Quant, Oncology Institute's Net Income towards Common Stockholders crashed by 24835040000.0% in 2021 and then soared by 203634.54% in 2022.
  • Quarter analysis of 5 years shows Oncology Institute's Net Income towards Common Stockholders stood at -$9.9 million in 2021, then dropped by 10.8% to -$11.0 million in 2022, then plummeted by 70.38% to -$18.8 million in 2023, then surged by 42.27% to -$10.8 million in 2024, then dropped by 27.19% to -$13.8 million in 2025.
  • Its Net Income towards Common Stockholders was -$13.8 million in Q3 2025, compared to -$14.0 million in Q2 2025 and -$19.6 million in Q1 2025.